Skip to content
City PM
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Opinion
  • DE
Tuesday 24 February 2026 9:02 pm  |  Updated:  Wednesday 25 February 2026 9:26 am

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

By: Business Wire

Add as a preferred source on Google

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 a.m. ET (2:10 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.

Alkermes management discusses strategy at TD Cowen 46th Annual Health Care Conference fireside chat event

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224148567/en/

Contact

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Company Logo
Company Logo
Read more

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Share this article

  • Facebook
  • X
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Businesswire

Categories

  • Conference
  • Webcast

Trending Articles

  • Government accelerates social media crackdown with midnight curfews

  • Bank of England governor opens door to ‘simplifying’ financial rulebook

  • First Trust Global Portfolios Management Limited Announces Distribution for certain sub-funds of First Trust Global Funds ICAV

  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

  • Clyde and Honour look keys to crack Hackwood

More from City PM

  • Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

    Business Wire
  • Alkermes to Report Second Quarter Financial Results on July 28, 2026

    Business Wire
  • Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

    Business Wire
  • Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

    Business Wire
  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

    Business Wire
  • Arm Announces Earnings Release Date for First Quarter Fiscal Year Ended 2027

    Business Wire
  • LivaNova to Announce Second-Quarter 2026 Results

    Business Wire

City PM — European politics, business and analysis.

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Topics

  • Business
  • Markets
  • AI
  • Technology
  • Opinion
  • Energy

More

  • Politics
  • Economics
  • Fintech
  • Legal
  • Sport
  • Life

Company

  • About City PM
  • Editorial Policy
  • Corrections
  • Contact
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
© 2026 City PM · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
About · Editorial Policy · Corrections · Contact · Privacy · Facebook